Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

Breast Cancer Research and Treatment

Volumn 105, Issue 3, 2007, Pages 277-286

  Zhang, Yunfei ^a   Ma, Baoan ^a   Zhou, Yong ^a   Zhang, Minghua ^a   Qiu, Xiuchun ^a   Sui, Yanfang ^b   Zhang, Xiumin ^b   Ma, Bin ^b   Fan, Qingyu ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic; CTL; Dendritic cells; Electrofusion; MCF 7

Indexed keywords

GAMMA INTERFERON;

ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL FUSION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ELECTROFUSION (CELL); HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL FUSION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS; HUMANS; INTERFERON TYPE II; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 35349015690     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9457-8     Document Type: Article

References (32)

1. McNeil BJ (1984) Value of bone scanning in neoplastic disease. Semin Nucl Med 14(4):277-286
2. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61-66
3. Heiser A, Coleman D, Dannull J, et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409-417
4. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
5. Steinman RM (1996) Dendritic cells and immune-based therapies. Exp Hematol 24(8):859-862
6. Banchereau J, Briere F, Caux C, et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811
7. Zhou Y, Bosch ML, Salgaller ML (2002) Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 25(4):289-303
8. Gong J, Chen D, Kashiwaba M, et al (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3(5):558-561
9. Gong J, Nikrui N, Chen D, et al (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165(3):1705-1711
10. Parkhurst MR, DePan C, Riley JP, et al (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of mhc class I and class II molecules. J Immunol 170(10):5317-5325
11. Koido S, Ohana M, Liu C, et al (2004) Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin Immunol 113(3):261-269
12. Koido S, Tanaka Y, Chen D, et al (2002) The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 168(5):2111-2117
13. Gong J, Avigan D, Chen D, et al (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97(6):2715-2718
14. Lindner M, Schirrmacher V (2002) Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur J Clin Invest 32(3):207-217
15. Wang J, Saffold S, Cao X, et al (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161(10):5516-5524
16. Hayashi T, Tanaka H, Tanaka J, et al (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104(1):14-20
17. Li J, Holmes LM, Franek KJ, et al (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50(9):456-462
18. Guo G, Chen S, Zhang J, et al (2005) Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine 23(45):5225-5230
19. Krause CJ, Carey TE, Ott RW, et al (1981) Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 107(11):703-710
20. Kass R, Agha J, Bellone S, et al (2003) In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res112(2):189-197
21. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus iuterleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179(4):1109-1118
22. Jaffee EM (1999) Immunotherapy of cancer. Ann N Y Acad Sci 886:67-72
23. Ward S, Casey D, Labarthe MC, et al (2002) Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 51(7):351-357
24. Trevor KT, Cover C, Ruiz YW, et al (2004) Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother 53(8):705-714
25. Michael A, Ball G, Quatan N, et al (2005) Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11(12):4469-4478
26. Lee WT, Shimizu K, Kuriyama H, et al (2005) Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg 132(5):755-764
27. Koido S, Hara E, Homma S, et al (2005) Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigen and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11(21):7891-7900
28. Jantscheff P, Spagnoli G, Zajac P, et al (2002) Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 51(7):367-375
29. Shu S, Cohen P (2001) Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 24(2):99-100
30. Phan V, Errington F, Cheong SC, et al (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9(9):1215-1219
31. Gabrijel M, Repnik U, Kreft M, et al (2004) Quantification of cell hybridoma yields with confocal microscopy and flow cytometry. Biochem Biophys Res Commun 314(3):717-723
32. Holmes LM, Li J, Sticca RP, et al (2001) A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunother 24(2):122-129